基于美国大型行政索赔数据库的成人起病Still病临床特征与合并症分析
本研究利用2009至2015年Truven MarketScan行政索赔数据,纳入106例成人起病Still病(AOSD)患者及1:5匹配对照530例,描述其临床特征、治疗模式与主要合并症。结果显示35.9%的AOSD患者符合基于索赔的Yamaguchi标准,严重感染率显著升高(率比2.58),而高脂血症和肥胖率显著降低。
要点
- AOSD患者严重感染风险显著增加(率比2.58,95%CI 1.53-4.37)。
- 35.9%的AOSD患者符合基于索赔的Yamaguchi标准。
- 常见治疗包括全身糖皮质激素(62.2%)、甲氨蝶呤(51%)和阿那白滞素(24.5%)。
核心结论
- 首次基于美国大型国家行政索赔数据库描述AOSD队列,识别了关键并发症、治疗和合并症。
研究设计与样本
- 回顾性行政索赔数据分析,AOSD队列106例,匹配对照530例,数据来自Truven MarketScan 2009-2015年。
主要发现
- AOSD患者平均年龄43.08岁(标准差13.9),女性占68.9%,平均观察750.12天(标准差637.6)。
- 35.9%的AOSD患者符合基于索赔的Yamaguchi标准,对照组为0.4%(P<0.05)。
- 严重AOSD相关并发症包括巨噬细胞活化综合征(4.7%)和急性呼吸窘迫综合征(12.3%)。
- 与匹配对照相比,严重感染率比2.58(95%CI 1.53-4.37,P=0.0004),高脂血症率比0.54(95%CI 0.35-0.85,P=0.008),肥胖率比0.30(95%CI 0.15-0.62,P=0.001)。
关键数值与推荐
- AOSD病例定义为≥1个ICD-10 M06.1医疗索赔代码。
- 基于索赔的Yamaguchi标准通过相关ICD-9和ICD-10代码识别。
临床怎么用
- 在AOSD管理中应警惕严重感染风险,并注意高脂血症和肥胖的较低发生率。
局限性
- 基于行政索赔数据,可能存在编码误分类和缺乏临床细节验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: We aimed to describe clinical characteristics, treatment patterns and major comorbidities of a US-based adult-onset Still's disease (AOSD) cohort. METHODS: Administrative claims data from Truven MarketScan were collected from 2009 to 2015. An AOSD case was defined as ≥1 M06.1 International Classification of Diseases 10th revision (ICD-10) medical claim code. We extracted data for the AOSD cohort (n = 106) and 1:5 matched controls (n = 530) without AOSD. Outcomes of interest and a novel claims-based set of Yamaguchi criteria were identified by relevant ICD 9th revision (ICD-9) and ICD-10 codes. Bivariate descriptive analyses were conducted on all variables. Comorbidity rates and rate ratios were calculated in AOSD cases and matched controls. Statistical significance of cohort differences was determined to compare AOSD cases and matched controls. RESULTS: The AOSD cohort, with a mean age of 43.08 (standard deviation, s.d. 13.9) years and with female predominance (68.9%) was observed over a mean of 750.12 (637.6) days. A total of 35.9% of AOSD patients fulfilled claims-based Yamaguchi criteria compared with 0.4% matched controls (P< 0.05). We identified severe AOSD-related complications, including macrophage activation syndrome (4.7%) and acute respiratory distress syndrome (12.3%). Treatment commonly involved systemic glucocorticoids (62.2%), MTX (51%) and anakinra (24.5%). Compared with matched controls, serious infections were significantly increased (rate ratio 2.58, 95% CI: 1.53, 4.37, P = 0.0004), while hyperlipidaemia (0.54, 95% CI: 0.35, 0.85; P = 0.008) and obesity (0.30, 95% CI: 0.15, 0.62; P = 0.001) were significantly decreased in AOSD patients. CONCLUSION: We characterized a first US-based AOSD cohort using a large national administrative claims database, and identified key complications, treatments and comorbidities.
引用
- Lenert A, Oh G, Ombrello MJ, et al. Clinical characteristics and comorbidities in adult-onset Still's disease using a large US administrative claims database. Rheumatology (Oxford). 2020. PMID: 31965185. doi:10.1093/rheumatology/kez622
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。